Under the Defence Product Act, the agency greenlit $32.4 million for Manus Bio, a biomanufacturing company in Waltham, Mass., and up to $12 million for Antheia, an active pharmaceutical ingredient manufacturer in Menlo Park, Calif.
With these funds, Manus and Antheia will focus on expanding capabilities to produce key starting materials and APIs for essential medicines, according to a Nov. 25 news release from ASPR.
